Carlos-Filipe Pereira

Carlos-Filipe Pereira

Center for Neuroscience and Cell Biology, University of Coimbra

Affiliated withUniversity of CoimbraLund University

Research Area

Biography

I am an assistant professor in Molecular Medicine at the Faculty of Medicine of Lund University and group leader of the Cell Reprogramming in Hematopoiesis and Immunity Laboratory. I have long held an interest in understanding how cell identity is acquired, maintained and ultimately modified or reversed. During my PhD, I have made my first contributions to the cellular reprogramming field by establishing cell fusion and heterokaryons as a new approach to study reprogramming mechanisms towards pluripotency. Of note I implicated the essential role of Polycomb repression in reprogramming. Then, during my postdoc, I brought cellular reprogramming concepts to hematopoeisis for the first time. I identified a combination of transcription factors that induces hemogenesis and established that cellular reprogramming approaches can inform the developmental specification of hematopoietic stem cells. My independent research group has now shown that cooperative transcription factor binding mediates hemogenic induction and pioneered cell fate reprogramming approaches in immunology with induced dendritic cells. This conceptual shift opens exciting opportunities to merge cellular reprogramming and cancer immunotherapy.

JoVE Journal Publications

ArticleTotal : 3
Year
Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program
Publication title

Cited by 1

2016
2019
2025

Other Publications

Article
Year
Red blood cells promote survival and cell cycle progression of human peripheral blood T cells independently of CD58/LFA-3 and heme compounds.

Cellular immunology| PubMed ID: 14572797

2003
2006
Heterokaryon-based reprogramming for pluripotency.

Current protocols in stem cell biology| PubMed ID: 19382123

2009
Reprogramming cell fates: insights from combinatorial approaches.

Annals of the New York Academy of Sciences| PubMed ID: 22901251

2012
Zfp281 mediates Nanog autorepression through recruitment of the NuRD complex and inhibits somatic cell reprogramming.

Proceedings of the National Academy of Sciences of the United States of America| PubMed ID: 22988117

2012
2013
"There will be blood" from fibroblasts.

Cell cycle (Georgetown, Tex.)| PubMed ID: 24335410

2014
2014
2015
Making a Hematopoietic Stem Cell.

Trends in cell biology| PubMed ID: 26526106

2016
2016
The stem cell niche finds its true north.

Development (Cambridge, England)| PubMed ID: 27531947

2016
2018
2018
2019
2019
Understanding and Modulating Immunity With Cell Reprogramming.

Frontiers in immunology| PubMed ID: 31921109

2019
2020
2020
Ihor R. Lemischka (1953-2017).

Cell stem cell| PubMed ID: 33253628

2018
2020
2021
Reprogramming, The Journal.

Cellular reprogramming| PubMed ID: 34101504

2021
2021
2021
Cell Fate Reprogramming in the Era of Cancer Immunotherapy.

Frontiers in immunology| PubMed ID: 34367185

2021
2021
2021
HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer.

Current oncology (Toronto, Ont.)| PubMed ID: 35049679

2021
2022
2022
2022
2022
2022
2022
2023
2023
2023
2023
2023
2023
2023
2023
2024
2024
2024
2024
2024
2024
In vivo dendritic cell reprogramming for cancer immunotherapy.

Science (New York, N.Y.)| PubMed ID: 39236156

2024
2024
2024
2024
Transcription factor-mediated reprogramming to antigen-presenting cells.

Current opinion in genetics & development| PubMed ID: 39721321

2025
2024
2025
RORγt-expressing dendritic cells are functionally versatile and evolutionarily conserved antigen-presenting cells.

Proceedings of the National Academy of Sciences of the United States of America| PubMed ID: 39993193

2025
2025
2025